KURN Kuros Biosciences AG

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

Kuros Biosciences AG / Key word(s): Annual Results
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

08.03.2024 / 07:00 CET/CEST

-    Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST

Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next-generation bone graft technologies, today announced that it will report its full-year financial results and provide a corporate update on its business on March 13, 2024.  Following the announcement, the company will host a video conference call at 3pm CET/10am US EST to discuss the results. 

To register for the video call, click . 

For further information, please contact:

Kuros Biosciences AG 
Daniel Geiger
Chief Financial Officer
t: 7
e: 		 LifeSci Advisors 
Sandya von der Weid
Investors
t:
e: 

About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic fusion technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across three continents and in 25,000 fusion surgeries. For more information on the company, its products and pipeline, visit .


End of Media Release
Language: English
Company: Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
Switzerland
Phone:
Fax:
E-mail:
Internet:
ISIN: CH0325814116
Valor: 32581411
Listed: SIX Swiss Exchange
EQS News ID: 1854131

 
End of News EQS News Service

1854131  08.03.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1854131&application_name=news&site_id=research_pool
EN
08/03/2024

Underlying

KURNKuros Biosciences AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kuros Biosciences AG

Free Trial
KURN Kuros Bioscienc...

Kuros Biosciences AG: 1 director

A director at Kuros Biosciences AG sold 30,000 shares at 31.110CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

KURN KUROS BIOSCIENCES AG
12/08/25 December 8, 2025 1 EN
 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Kuros Biosciences announces enrollment of first patient in ASTRA study...

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion Schlieren (Zürich), Switzerland, December 2, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced that the first patient has been enrolled in its global ASTRA (Ankle Subtalar arThrodesis Randomized Assessment) stu...

December 2, 2025 1 EN
 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthca...

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference Schlieren (Zürich), Switzerland, November 26, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, will present at the Piper Sandler 37th Annual Healthcare Conference, taking place December 2–4, 2025 at The Lotte New York Palace in New York City. The Company’s presentation will highlight continued commercial momentum, clinical advancement across the MagnetOs portfolio, and ong...

November 26, 2025 1 EN
 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Kuros Biosciences increases the annual guidance for 2025, The company ...

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025 Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025 The company reports 77% year-over-year increase for the first nine months of 2025 Financial & Operational Highlights Total Medical Device sales rose by 77% to USD 101.1 million for the first nine months of 2025 (9M 2024: USD 57.2 million)Direct MagnetOs™ sales increased by 76% to USD 99.7 million for the first nine months of 2...

October 16, 2025 1 EN
 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery Sy...

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Schlieren (Zürich), Switzerland – September 30, 2025 – Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative biologic technologies, today announced the full commercial launch of the MagnetOs™ MIS Delivery System. Purpose-built for Minimally Invasive Surgical (MIS) procedures, the system is designed to meet every surgeon’s need in bone graft delivery. It will be showcased at the Kuros booth and featur...

September 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch